Novartis AG Files Q3 2025 Financial Report on Form 6-K
Ticker: NVSEF · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, quarterly-filing, foreign-private-issuer
TL;DR
Novartis dropped its Q3 2025 financials, check the 6-K for the deets.
AI Summary
Novartis AG filed a Form 6-K on October 28, 2025, reporting on its financial performance for the period ending September 30, 2025. The filing includes Exhibits 99.1 and 99.2, which contain the Financial Report for Q3 2025 and a Condensed Financial Report, respectively. Paul Penepent, Head of Financial Reporting and Accounting, signed the report on behalf of Novartis AG.
Why It Matters
This filing provides investors with key financial data for Novartis AG's third quarter of 2025, offering insights into the company's performance and financial health.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) that provides standard quarterly financial information.
Key Players & Entities
- Novartis AG (company) — Registrant
- Paul Penepent (person) — Head Financial Reporting and Accounting
- October 28, 2025 (date) — Filing Date
- September 30, 2025 (date) — Reporting Period End Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed by Novartis AG to report on its financial performance for the period ending September 30, 2025.
What exhibits are included with this filing?
This filing includes Exhibit 99.1 (Financial Report Q3 2025) and Exhibit 99.2 (Condensed Financial Report).
Who signed the Form 6-K on behalf of Novartis AG?
The Form 6-K was signed by Paul Penepent, Head of Financial Reporting and Accounting.
What is the filing date of this report?
The report was filed on October 28, 2025.
What is Novartis AG's principal executive office address?
Novartis AG's principal executive offices are located at Lichtstrasse 35, 4056 Basel, Switzerland.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2025-10-28 06:07:00
Filing Documents
- a251028-6k.htm (6-K) — 14KB
- a251028-99_1.htm (EX-99) — 231KB
- a251028-99_2.htm (EX-99) — 1336KB
- logorm.jpg (GRAPHIC) — 29KB
- coverifr.jpg (GRAPHIC) — 95KB
- 0001114448-25-000003.txt ( ) — 1733KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Novartis AG Date: October 28, 2025 By: /s/ PAUL PENEPENT Name: Paul Penepent Title: Head Financial Reporting and Accounting